SecBot SecBot
8-K ·Filed May 11, 2026

AUPH

Aurinia Pharmaceuticals Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001140361-26-020402
8-K material event: Items 2.01
Actionable Insight • Neutral

The acquisition adds Kezar's pipeline to Aurinia's portfolio, but the CVR structure means future payouts depend on Kezar's clinical milestones. Monitor Kezar's development progress and any CVR-related disclosures for potential upside or impairment.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.72
T+0 close · May 11, 2026 · via day close
Latest settled
−3.37%
T+60 · $15.19
Vs SPY
−7.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $15.72entry
  2. T+1 · 6mo ago +1.72%α +1.85% · $15.99
  3. T+5 · 6mo ago −0.76%α −0.68% · $15.60
  4. T+20 · 5mo ago +0.38%α +0.69% · $15.78
  5. T+60 · 3mo ago −3.37%α −7.76% · $15.19

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merger. Shareholders received $6.955 per share in cash plus one contingent value right (CVR) per share. The deal closed on May 11, 2026, with 80.24% of Kezar shares tendered, and the remaining shares were acquired in a subsequent merger without a stockholder vote.

Key Facts

  • Aurinia completed the acquisition of Kezar Life Sciences for $6.955 per share in cash plus one CVR per share.
  • The tender offer expired on May 8, 2026, with 5,927,580 shares (80.24% of outstanding) validly tendered.
  • The merger closed on May 11, 2026, under Section 251(h) of the DGCL without a stockholder vote.
  • Outstanding in-the-money stock options were cancelled and converted into cash and CVRs; out-of-the-money options were cancelled for no consideration.
  • The CVR Agreement was dated May 11, 2026, with Broadridge as Rights Agent and Fortis Advisors as Representative.

Financial Impact

Total cash consideration for the 5,927,580 shares tendered is approximately $41.2 million (5,927,580 × $6.955). Total deal value including remaining shares and option consideration is not disclosed.

cashdilution

Risk Factors

  • CVR payouts are contingent on future milestones and may never materialize.
  • Integration risks from absorbing Kezar's operations and pipeline.
  • Cash outlay for the acquisition may pressure Aurinia's balance sheet.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-020402
Document: 0001140361-26-020402-index-headers.html0001140361-26-020402
Document: 0001140361-26-020402-index.html0001140361-26-020402
Document: 0001140361-26-020402.txt0001140361-26-020402

Track record

7 reports on AUPH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +10.59% at T+60 after the Feb 26, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $15.42 Now $15.48 +0.39% settles Feb 12
  2. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $16.56 Now $15.48 −6.52% settles Feb 1
  3. Oct 30, 202617d ago 8-K Neutral 5/10 Entry $16.65 Now $15.48 −7.03% settles Jan 28
  4. Aug 6, 202614w ago 8-K Bullish 6/10 Entry $16.13 to $16.65 Now $15.48 −4.03% ▲ +3.22% +4.89% vs SPY
  5. Jun 2, 202623w ago Insider Buy Bullish 6/10 Entry $15.67 to $16.48 Now $15.48 −1.21% ▲ +5.14% +2.90% vs SPY
  6. May 11, 202627w ago 8-K Neutral 5/10 Viewing Entry $15.72 to $15.19 Now $15.48 −1.53% ▼ −3.37% −7.76% vs SPY
  7. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $13.97 to $15.45 Now $15.48 +10.81% ▲ +10.59% +2.84% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026